Aurora Cannabis (ACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

IDEAYA Biosciences (IDYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Investment analysts at Zacks Research reduced their Q1 2025 earnings per share estimates for shares of Onsemi in a note ...

Rapt Therapeutics (RAPT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...

Research analysts at Zacks Research increased their Q1 2025 earnings per share estimates for The PNC Financial Services Group ...

The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock ...

Building a successful investment portfolio takes skill and hard work, no matter if you're a growth, value, income, or momentum-focused investor. But what's the best way to find the right combination ...

A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts ...

Zacks All-Cap Core Fund earns an Average Process Pillar rating. The predominant contributor to the rating is the fund's excellent long-term risk-adjusted performance. This can be seen in its ten ...

VALE (VALE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.